Navigation Links
Genaera Receives Non-Compliance Notice from Nasdaq
Date:5/27/2009

PLYMOUTH MEETING, Pa., May 27 /PRNewswire-FirstCall/ -- Genaera Corporation ("the Company") (Nasdaq: GENR) today announced that it has received notification from Nasdaq stating that Genaera is no longer in compliance with Nasdaq Marketplace Rule 5250(c)(1) for continued listing because the Company has not yet filed its Form 10-Q for the period ended March 31, 2009. Under Nasdaq rules, the Company has 60 calendar days from the date of the Nasdaq notification letter to submit a plan to regain compliance with Nasdaq's continued listing requirements.

Genaera previously announced on April 28, 2009 that its Board of Directors approved a Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution"), subject to stockholder approval. The Company intends to hold a special meeting of stockholders on June 4, 2009 to seek approval of the Plan of Dissolution and has filed definitive proxy materials with the Securities and Exchange Commission ("SEC"). If stockholder approval of the Plan of Dissolution is obtained at the special meeting, the Company intends to file a certificate of dissolution and delist its common stock from Nasdaq.

About Genaera

Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our Web site at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as from other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


'/>"/>
SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
5. Genaera Corporation Announces 2007 Financial Results
6. Genaera Corporation Announces First Quarter Financial Results
7. Genaera Corporation to Present at BIO Business Forum
8. Genaera Corporation Elects Paul K. Wotton to Board of Directors
9. Genaera Corporation Announces Second Quarter Financial Results
10. Genaera to Present at BIO-Europe 2008
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell Consulting’s ... and life sciences industries, continue to be in demand for their insights and ... be speaking on “The State of Information Governance in the Biopharmaceutical Industry” at ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced the release of Limfinity® version 6.5, a content-packed update to the Limfinity® ... to gain a larger and more diverse base of customers among labs and ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... the CTNext board of directors has formed a Higher Education Entrepreneurship Advisory Committee ... composed of institution presidents and other high-ranking representatives from 35 higher education institutions ...
(Date:6/20/2017)... ... June 20, 2017 , ... HorizonScan is providing food and ... most likely threat to their products at the annual IFT conference in Las ... food expo attracts over 20,000 attendees representing food science professionals from over 90 ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
Breaking Biology News(10 mins):